Inventiva S.A.
IVA
Price:
$2.615
Market Cap:
$218.05M
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing...[Read more]
Industry
Biotechnology
IPO Date
2020-07-10
Stock Exchange
NASDAQ
Ticker
IVA
PE Ratio
[-1.21]
ROE
[524.89%]
Current Ratio
[0.96]
Dividend Yield
[0%]
Enterprise Value
[228.20M]
Dividend History
The ROE as of November 2024 (TTM) for Inventiva S.A. (IVA) is 524.89%
According to Inventiva S.A.’s latest financial reports and current stock price. The company's current ROE is 524.89%. This represents a change of 150.39% compared to the average of 209.63% of the last 4 quarters.
Inventiva S.A. (IVA) Historical ROE (quarterly & annually)
How has IVA ROE performed in the past?
The mean historical ROE of Inventiva S.A. over the last ten years is -6.83%. The current 524.89% ROE has changed -7784.84% with respect to the historical average. Over the past ten years (40 quarters), IVA's ROE was at its highest in in the June 2023 quarter at 720.87%. The ROE was at its lowest in in the December 2022 quarter at -54.55%.
Average
-6.83%
Median
-27.68%
Minimum
-119.35%
Maximum
344.74%
Inventiva S.A. (IVA) ROE by Quarter and Year
Discovering the peaks and valleys of Inventiva S.A. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 113.67%
Maximum Annual ROE = 344.74%
Minimum Annual Increase = -388.85%
Minimum Annual ROE = -119.35%
| Year | ROE | Change |
|---|---|---|
| 2023 | 344.74% | -388.85% |
| 2022 | -119.35% | 113.67% |
| 2021 | -55.85% | 96.43% |
| 2020 | -28.43% | -61.05% |
| 2019 | -73.01% | 33.78% |
| 2018 | -54.57% | 102.76% |
| 2017 | -26.92% | 36.48% |
| 2016 | -19.72% | -4.40% |
| 2015 | -20.63% | 41.80% |
| 2014 | -14.55% | 20.33% |
Inventiva S.A. (IVA) Average ROE
How has IVA ROE performed in the past?
The current ROE of Inventiva S.A. (IVA) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
56.51%
5-year avg
13.62%
10-year avg
-6.83%
Inventiva S.A. (IVA) ROE vs. Peers
How is IVA’s ROE compared to its peers?
Inventiva S.A.’s ROE is greater than Mineralys Therapeutics, Inc. (-55.92%), greater than Eliem Therapeutics, Inc. (-47.03%), greater than Anebulo Pharmaceuticals, Inc. (-184.40%), greater than Janux Therapeutics, Inc. (-10.46%), greater than Rezolute, Inc. (-69.83%), greater than Monte Rosa Therapeutics, Inc. (-62.68%), greater than NewAmsterdam Pharma Company N.V. (-53.79%), greater than Cullinan Oncology, Inc. (-26.54%), greater than Compass Therapeutics, Inc. (-28.67%), greater than Arcellx, Inc. (-8.28%), greater than Ventyx Biosciences, Inc. (-54.94%), greater than Immunocore Holdings plc (-14.67%), greater than Vaxcyte, Inc. (-23.53%), less than DICE Therapeutics, Inc. (56.07%), less than Verrica Pharmaceuticals Inc. (1.30%), greater than LianBio (-21.53%), greater than Edgewise Therapeutics, Inc. (-26.83%), greater than Vigil Neuroscience, Inc. (-83.89%), greater than Innate Pharma S.A. (-84.39%), greater than HCW Biologics Inc. (-2516.87%), less than Inhibrx Biosciences, Inc. (1.45%),
| Company | ROE | Market cap |
|---|---|---|
| -55.92% | $621.09M | |
| -47.03% | $342.68M | |
| -184.40% | $37.86M | |
| -10.46% | $2.64B | |
| -69.83% | $284.50M | |
| -62.68% | $521.60M | |
| -53.79% | $1.87B | |
| -26.54% | $730.17M | |
| -28.67% | $205.01M | |
| -8.28% | $4.89B | |
| -54.94% | $130.81M | |
| -14.67% | $1.61B | |
| -23.53% | $11.04B | |
| 56.07% | $2.27B | |
| 1.30% | $45.35M | |
| -21.53% | $34.47M | |
| -26.83% | $3.05B | |
| -83.89% | $130.41M | |
| -84.39% | $131.95M | |
| -2516.87% | $29.12M | |
| 1.45% | $203.82M |
Build a custom stock screener for Inventiva S.A. (IVA) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Inventiva S.A. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Inventiva S.A. (IVA) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Inventiva S.A. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Inventiva S.A.'s ROE?
How is the ROE calculated for Inventiva S.A. (IVA)?
What is the highest ROE for Inventiva S.A. (IVA)?
What is the 3-year average ROE for Inventiva S.A. (IVA)?
What is the 5-year average ROE for Inventiva S.A. (IVA)?
How does the current ROE for Inventiva S.A. (IVA) compare to its historical average?